AIMS/HYPOTHESIS: Heart failure has been suggested to increase the risk of developing diabetes. We investigated the relation between heart failure severity, defined by loop-diuretic dosage, and the risk of developing diabetes in a nationwide cohort of patients with heart failure. METHODS: We followed all Danish patients discharged from hospitalisation for first-time heart failure in 1997-2010, without prior use of hypoglycaemic agents, until a claimed prescription for hypoglycaemic agents, death or 31 December 2010. The association of loop-diuretic dosage (furosemide equivalents) 90 days after discharge (study baseline) with risk of diabetes was estimated by multivariate Cox regression models. RESULTS: In total, 99,362 patients were included and divided into five loop-diuretic dose groups: 30,838 (31%) used no loop diuretics; 24,389 (25%) used >0-40 mg/day; 17,355 (17%) used >40-80 mg/day; 11,973 (12%) used >80-159 mg/day; and 14,807 (15%) used ≥160 mg/day. A total of 7,958 patients (8%) developed diabetes. Loop-diuretic dosages were associated with an increased risk of developing diabetes in a dose-dependent manner. Concomitant use of renin-angiotensin system inhibitors (RASis) attenuated the risk (p value for interaction <0.0001). Compared with patients using no loop diuretics (group 1), the adjusted HRs (95% CI) for developing diabetes for groups 2-5 respectively were 1.16 (1.07, 1.26), 1.35 (1.24, 1.46), 1.48 (1.35, 1.62) and 1.76 (1.61, 1.92) with RASi treatment, and 2.06 (1.83, 2.32), 2.28 (2.01, 2.59), 2.88 (2.52, 3.30) and 3.02 (2.66, 3.43) without RASi treatment. CONCLUSIONS/ INTERPRETATION: In a nationwide cohort of patients with heart failure, severity of heart failure was associated with a stepwise increased risk of developing diabetes. Increased awareness of risk of diabetes associated with severe heart failure is warranted.
AIMS/HYPOTHESIS: Heart failure has been suggested to increase the risk of developing diabetes. We investigated the relation between heart failure severity, defined by loop-diuretic dosage, and the risk of developing diabetes in a nationwide cohort of patients with heart failure. METHODS: We followed all Danish patients discharged from hospitalisation for first-time heart failure in 1997-2010, without prior use of hypoglycaemic agents, until a claimed prescription for hypoglycaemic agents, death or 31 December 2010. The association of loop-diuretic dosage (furosemide equivalents) 90 days after discharge (study baseline) with risk of diabetes was estimated by multivariate Cox regression models. RESULTS: In total, 99,362 patients were included and divided into five loop-diuretic dose groups: 30,838 (31%) used no loop diuretics; 24,389 (25%) used >0-40 mg/day; 17,355 (17%) used >40-80 mg/day; 11,973 (12%) used >80-159 mg/day; and 14,807 (15%) used ≥160 mg/day. A total of 7,958 patients (8%) developed diabetes. Loop-diuretic dosages were associated with an increased risk of developing diabetes in a dose-dependent manner. Concomitant use of renin-angiotensin system inhibitors (RASis) attenuated the risk (p value for interaction <0.0001). Compared with patients using no loop diuretics (group 1), the adjusted HRs (95% CI) for developing diabetes for groups 2-5 respectively were 1.16 (1.07, 1.26), 1.35 (1.24, 1.46), 1.48 (1.35, 1.62) and 1.76 (1.61, 1.92) with RASi treatment, and 2.06 (1.83, 2.32), 2.28 (2.01, 2.59), 2.88 (2.52, 3.30) and 3.02 (2.66, 3.43) without RASi treatment. CONCLUSIONS/ INTERPRETATION: In a nationwide cohort of patients with heart failure, severity of heart failure was associated with a stepwise increased risk of developing diabetes. Increased awareness of risk of diabetes associated with severe heart failure is warranted.
Authors: Charlotte Andersson; Mette L Norgaard; Peter R Hansen; Emil L Fosbøl; Michelle Schmiegelow; Peter Weeke; Jonas B Olesen; Jakob Raunsø; Casper H Jørgensen; Allan Vaag; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason Journal: Eur J Heart Fail Date: 2010-09-23 Impact factor: 15.534
Authors: Hans Lithell; Lennart Hansson; Ingmar Skoog; Dag Elmfeldt; Albert Hofman; Bertil Olofsson; Peter Trenkwalder; Alberto Zanchetti Journal: J Hypertens Date: 2003-05 Impact factor: 4.844
Authors: E L Fosbøl; G H Gislason; S Jacobsen; F Folke; M L Hansen; T K Schramm; R Sørensen; J N Rasmussen; S S Andersen; S Z Abildstrom; J Traerup; H E Poulsen; S Rasmussen; L Køber; C Torp-Pedersen Journal: Clin Pharmacol Ther Date: 2008-11-05 Impact factor: 6.875
Authors: Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Matlooba A AlZadjali; Valerie Godfrey; Faisel Khan; AnnaMaria Choy; Alexander S Doney; Aaron K Wong; John R Petrie; Allan D Struthers; Chim C Lang Journal: J Am Coll Cardiol Date: 2009-03-03 Impact factor: 24.094
Authors: Charlotte Andersson; Asya Lyass; Martin G Larson; Sander J Robins; Ramachandran S Vasan Journal: Diabetologia Date: 2015-09-26 Impact factor: 10.122
Authors: Robert Scragg; Alistair W Stewart; Debbie Waayer; Carlene M M Lawes; Les Toop; John Sluyter; Judy Murphy; Kay-Tee Khaw; Carlos A Camargo Journal: JAMA Cardiol Date: 2017-06-01 Impact factor: 14.676
Authors: Osnat Itzhaki Ben Zadok; Ran Kornowski; Ilan Goldenberg; Robert Klempfner; Yoel Toledano; Yitschak Biton; Enrique Z Fisman; Alexander Tenenbaum; Gregory Golovchiner; Ehud Kadmon; Alexander Omelchenko; Tuvia Ben Gal; Alon Barsheshet Journal: Cardiovasc Diabetol Date: 2017-08-14 Impact factor: 9.951
Authors: Nadia Iannino; Amine Nasri; Agnès Räkel; Anique Ducharme; Kim Lachance; Normand Racine; Simon de Denus; Maxime Tremblay-Gravel; Annik Fortier; Michel White Journal: J Transplant Date: 2018-11-08